Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 03, 2023 1:43pm
266 Views
Post# 35201113

RE:Watch Dopesick on Disney Plus

RE:Watch Dopesick on Disney Plus
Forestview wrote: Hey all, happy new year.  Like many of you, I took the time to binge watch some TV over the holidays.  One show I recommend all of you to watch is Dopesick, based on Purdue Pharma's development of OxyContin, and how its highly addictive nature (which Purdue grossly downplayed) decimated the lives of tens of thousands of people.  If anyone wonders what ATE is doing, and the potential impact it may have on the world, this series will reinforce its importance.  

I hope ATE continues to make progress in 2023, there is a real, tangible market for Otena, and others.  

Good luck longs.  


hahaha - well said Forestview.
I know the story of Purdue but I'm sure there is a lot more information in Dopesick.
Will be watching !!!

2 million Americans (every year) "may" fall into the opioid trap after surgery.  We have to get away from them.  Similarly we need to get away from NSAIDs and bleeding ulcers.

I will be putting out a few tid-bits about ATE in 2023 as per the latest webinar on their website (with Radius Research).  After watching Dopesick, I recommend viewing this webinar before it is removed (6 months after it first aired - I think).

In the second half of 2023, we'll know where ATE stands as a potential game-changer in post-op pain to displace Opioids and NSAIDs.  We'll also know what the game plan is for chronic pain.  Many options available.  Just takes time to get it right - IMO !!!

Good Luck !
 
<< Previous
Bullboard Posts
Next >>